Targeted interleukin-22 therapy improves glycemic control, steatohepatitis, and fibrosis in experimental models of metabolic dysfunction-associated steatohepatitis

H. Sajiir, S. Keshvari,K. Y. Wong, D. Borg, A. Mueller, M. Moniruzzaman,R. Wang, A. Fotheringham, V. Schreiber, Y. Sheng, J. Lockett, G. Ramm, G. Macdonald, J. B. Prins, M. A. Mcguckin, S. Z. Hasnain

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY（2023）

引用 0|浏览0